A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy

Eli Lilly and Company0 个研究点目标入组 125 人开始时间: 2012年3月7日最近更新: 2022年1月4日

适应症

试验速览

暂无简介。

•Patients with unresectable or metastatic pancreas cancer
•ECOG Performance status = 2
•Adequate organ function
•Have an estimated life expectancy of at least 12 weeks and in the judgment of the investigator, will be able to complete at least 2 cycles of treatment
•Ability to perform the indicated functional performance measures at baseline.
•Females with child bearing potential must have a negative serum pregnancy test = 7 days prior to the first dose of study drug.
•Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 3 months after discontinuation from study therapy.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 25
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 95

•Have received prior systemic therapy for unresectable/metastatic pancreas cancer.
•Have underlying muscle disease or history of muscle disease
•Have evidence or recent history of significant psychiatric disease such as dementia/Alzheimer’s, schizophrenia, or bipolar disorder.
•Currently taking medications that are considered both muscle building and performance enhancing (for example, androgen therapies, or anabolic steroids)

发起方